Exact Sciences Sues Rival Geneoscopy Related To Colon Cancer Test Cologuard Patent - Exact Sciences (NASDAQ:EXAS)
Exact Sciences Corp (NASDAQ: EXAS) filed a patent infringement lawsuit against Geneoscopy in the U.S.
Source: benzinga.com
Page 18 - Sciences Corp News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Sciences Corp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Sciences Corp Today - Breaking & Trending Today
180 Life Sciences Corp. (NASDAQ:ATNF) Short Interest Up 21.2% in October
180 Life Sciences Corp. (NASDAQ:ATNF – Get Free Report) was the target of a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 126,700 shares, an increase of 21.2% from the October 15th total of 104,500 shares. Currently, 2.3% of the company’s shares are sold […]
Source: modernreaders.com
180 Life Sciences Corp. (NASDAQ:ATNF) Short Interest Up 21.2% in October
180 Life Sciences Corp. (NASDAQ:ATNF – Get Free Report) saw a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 126,700 shares, a growth of 21.2% from the October 15th total of 104,500 shares. Based on an average daily volume of 140,400 shares, the short-interest […]
Source: wkrb13.com
Exact Sciences Corporation (NASDAQ:EXAS) Q3 2023 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Exact Sciences Third Quarter 2023 Earnings Conference Call.
Source: insidermonkey.com
Exact Sciences turns small profit in Q3 after big losses
The biomedical giant best known for its Cologuard at-home colon cancer screening test reported third-quarter net income of $0.8 million, or $0.00 per share, on revenue of $628 million.
Source: lacrossetribune.com